Pfizer Isn't Expecting to Make Any Big Acquisition in the Next Couple of Years, but It's Planning to Do This Instead

1 hour ago 1

David Jagielski, CPA, The Motley Fool

Mon, June 22, 2026 astatine 7:18 AM CDT 3 min read

Acquisitions tin beryllium a double-edged sword for companies, arsenic they tin rapidly bolster gross and maturation opportunities but besides adhd costs and inefficiencies. Healthcare elephantine Pfizer (NYSE: PFE) has been progressive successful galore acquisitions successful caller years arsenic it has worked to fortify its prospects; a large hazard for the banal has been uncertainty astir wherever its maturation volition travel from, peculiarly arsenic it faces patent cliffs connected cardinal drugs.

One of the largest deals Pfizer made was the $43 cardinal acquisition of oncology institution Seagen successful 2023. It was a large acquisition that gave it immoderate promising cancer-fighting medicines. But Pfizer isn't expecting to marque important deals similar this successful the adjacent future. Here's however it plans to set its strategy and what that could mean for investors.

Missed Nvidia successful 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" awesome flashed for a little-known chipmaker called Nvidia. For the archetypal clip successful years, that aforesaid "Total Conviction" awesome is flashing for a institution 1/100th the size of Nvidia. Continue »

A radical of scientists looking astatine a report.

Pfizer looks to instrumentality a interruption from acquisitions

When a institution is aggressively pursuing acquisitions, it tin marque it hard to debar rising costs, arsenic it whitethorn incur acquisition-related expenses and go bloated with further workers and overhead.

On Pfizer's astir caller net call, CEO Albert Bourla was asked if determination would beryllium immoderate much important acquisitions successful the adjacent future. Bourla indicated that nothing's connected the skyline and that the healthcare institution volition alternatively absorption connected enhancing its antithetic businesses with artificial quality (AI).

"We deliberation that close now, successful the adjacent 2 years, it is the clip to execute connected AI translation of these organizations. That requires not the disruption of a mega merger."

Bourla sees tremendous imaginable with AI to make caller medicines much quickly. Not lone could this accelerate the company's semipermanent growth, but it whitethorn besides output greater outgo savings and efficiency, starring to stronger fiscal results.

Does this quality marque Pfizer's banal a amended buy?

Slowing down its acquisition strategy could beryllium an advantageous determination for Pfizer, peculiarly arsenic it works to usage AI to amended its processes. If these AI transformations effect successful stronger net and semipermanent maturation prospects, it's what the banal whitethorn request to get retired of its funk; shares of Pizer are down 35% successful the past 5 years, arsenic adjacent a debased valuation hasn't been capable of a crushed to entice investors to bargain the stock.

Read Entire Article